Vaccine Contract Manufacturing Market - Global Forecast 2026-2032

The Vaccine Contract Manufacturing Market is projected to reach USD 6.56 Billion in 2026. It is expected to continue growing at a CAGR of 9.53%, reaching USD 11.43 Billion by 2032.

The vaccine contract manufacturing market is being reshaped by demand for flexible capacity, faster technology transfer, regulatory-grade quality systems, and resilient global supply chains. Vaccine developers increasingly rely on contract development and manufacturing organizations (CDMOs) for drug substance production, fill-finish operations, analytical testing, packaging, cold-chain readiness, and commercial scale-up across mRNA, recombinant protein, viral vector, conjugate, inactivated, and live-attenuated vaccine platforms.

The executive summary frames vaccine contract manufacturing as strategic health security infrastructure rather than a transactional outsourcing category. Verified priorities from the World Health Organization, CEPI, Gavi, UNICEF procurement systems, national health agencies, and stringent regulators including the U.S. FDA and European Medicines Agency show that pandemic preparedness, routine immunization, equitable access, and localized vaccine production are now central to long-term biomanufacturing investment and partnership decisions.

Transformative Shifts in the Vaccine Manufacturing Landscape

The landscape is shifting from single-platform, campaign-based vaccine production toward modular, multi-platform manufacturing networks. mRNA, recombinant protein, viral vector, conjugate, and inactivated vaccine technologies require differentiated upstream, downstream, aseptic fill-finish, sterility assurance, and quality-control capabilities, encouraging developers to partner with CDMOs that can manage complexity across platforms and lifecycle stages.

Another major shift is the regionalization of capacity. Governments are using procurement, public-private partnerships, national stockpiling, and biosecurity policies to reduce reliance on concentrated supply chains. At the same time, regulators are emphasizing data integrity, GMP compliance, pharmacovigilance readiness, and robust comparability packages, making proven tech transfer, validation, batch documentation, and regulatory submission support core differentiators for vaccine manufacturing partners.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative gains across vaccine contract manufacturing by improving process development, predictive maintenance, deviation management, demand planning, raw-material risk monitoring, and batch-release analytics. In regulated GMP environments, AI is most valuable when paired with validated data systems, human oversight, audit trails, cybersecurity controls, and quality-by-design principles.

For CDMOs, AI can shorten development cycles by identifying critical process parameters earlier, supporting digital twins for scale-up, and detecting quality trends before they become failures. The impact is cumulative because each validated data set strengthens future campaigns, improving manufacturing reliability, capacity utilization, technology transfer consistency, and client confidence without replacing regulatory accountability or qualified person oversight where required.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is a critical hub for vaccine contract manufacturing due to large-scale capacity in India and China, advanced biomanufacturing in Japan and South Korea, and growing sovereign capacity in Australia and Southeast Asia. India’s role is reinforced by high-volume vaccine producers and its long-standing participation in global immunization supply, including UNICEF and Gavi-supported channels, while South Korea and Japan continue to invest in biologics, mRNA, viral vector, and fill-finish infrastructure. Australia and ASEAN markets are strengthening preparedness through domestic manufacturing programs, regulatory cooperation, and cold-chain modernization.

North America remains anchored by the United States and Canada, where BARDA, NIH, Health Canada, and FDA-regulated manufacturing ecosystems support advanced vaccine development, emergency preparedness, GMP compliance, and public-private capacity programs. Latin America is strengthened by Brazil’s established public vaccine institutions, Mexico’s proximity to North American supply chains, and PAHO-supported regional health cooperation, which together support technology transfer, fill-finish expansion, and regional immunization resilience.

Europe benefits from EMA standards, the European Health Emergency Preparedness and Response Authority, coordinated procurement experience, and strong CDMO clusters in Germany, France, Italy, Spain, and the United Kingdom. The Middle East is investing in localization through healthcare diversification agendas, especially across Gulf economies seeking biologics, packaging, and fill-finish capabilities. Africa is gaining momentum through the African Union and Africa CDC’s Partnerships for African Vaccine Manufacturing, which targets expanded continental vaccine production by 2040 and supports a shift from import dependence toward sustainable regional manufacturing.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN is increasingly relevant as member states strengthen regulatory cooperation, cold-chain systems, and biopharmaceutical investment to reduce dependence on imported vaccines and improve outbreak-response readiness. The GCC is using healthcare localization strategies, procurement policy, sovereign investment, and industrial diversification to attract fill-finish, packaging, quality-control, and biologics manufacturing partnerships aligned with national health security goals.

The European Union plays a central role through EMA-aligned regulatory oversight, HERA preparedness planning, coordinated funding for health resilience, and cross-border mechanisms that support vaccine availability during public health emergencies. BRICS countries add manufacturing depth through China, India, Brazil, Russia, and South Africa, combining large domestic immunization requirements with expanding vaccine production capacity, technology transfer initiatives, and public-sector immunization programs.

The G7 influences vaccine contract manufacturing through financing, innovation policy, global health commitments, pandemic preparedness initiatives, and regulatory convergence among high-income markets. NATO is not a vaccine regulator, but its focus on resilience, civil preparedness, logistics, and medical countermeasures reinforces the strategic importance of secure vaccine supply chains, protected manufacturing infrastructure, and reliable access to critical biologics during crises.

Key Country Insights Across Major Vaccine Contract Manufacturing Markets

The United States leads through advanced R&D, FDA-regulated GMP manufacturing, BARDA-supported preparedness, NIH-backed vaccine science, and a deep CDMO base spanning drug substance, fill-finish, analytical testing, and cold-chain logistics. Canada is rebuilding domestic biomanufacturing capacity through national life sciences and pandemic preparedness programs, while Mexico benefits from proximity to North American supply chains, regional trade integration, and growing healthcare manufacturing capabilities. Brazil is Latin America’s key vaccine manufacturing market through established public-sector institutions and technology transfer experience, and the United Kingdom remains important for life sciences innovation, clinical development, regulatory capability, and vaccine platform research.

In Europe, Germany, France, Italy, and Spain provide strong biologics, aseptic manufacturing, quality-system expertise, and EMA-aligned regulatory experience, while Russia maintains domestic vaccine production capacity and a public-sector focus on self-sufficiency. In Asia-Pacific, China and India offer scale across vaccine production, supplier ecosystems, and domestic immunization demand, with India especially important for global dose supply and established participation in international procurement channels. Japan, Australia, and South Korea add high-quality manufacturing, government-backed preparedness, advanced biologics capabilities, and growing interest in mRNA, recombinant protein, and next-generation vaccine technologies.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize platform flexibility, validated tech transfer, and resilient supplier networks. CDMOs that can support multiple vaccine modalities, manage GMP documentation, and provide integrated drug substance, fill-finish, testing, labeling, serialization, and cold-chain services will be better positioned for commercial programs, clinical pipelines, and emergency-response demand.

Firms should also invest in digital quality systems, AI-enabled process monitoring, dual sourcing, workforce training, and regional manufacturing partnerships. Strategic success depends on aligning capacity expansion with regulator expectations, public-sector procurement priorities, biosafety requirements, cold-chain specifications, and client demand for speed without compromising safety, potency, sterility, traceability, or compliance.

Research Methodology

Research methodology is developed using a secondary-research framework grounded in verified public-domain sources, including international health agencies, regulatory authorities, government preparedness programs, public procurement references, scientific literature, and recognized industry bodies. The analysis emphasizes evidence from WHO, CEPI, Gavi, UNICEF procurement practices, FDA, EMA, Africa CDC, PAHO, national immunization programs, and government-backed biomanufacturing initiatives.

The methodology avoids unsupported market sizing claims and prioritizes traceable indicators such as regulatory policy, manufacturing investments, platform adoption, public-private partnerships, capacity-building programs, localization strategies, technology transfer activity, and quality-system requirements. Insights are synthesized to identify structural trends in vaccine contract manufacturing without presenting market estimation, market share, or market forecasting.

Conclusion

Vaccine contract manufacturing is becoming a core pillar of global health security, routine immunization, and biopharmaceutical competitiveness. The strongest opportunities are emerging where technical platform breadth, regulatory compliance, regional access, supply-chain resilience, and verified quality infrastructure intersect.

As vaccine pipelines diversify and governments strengthen preparedness systems, CDMOs with validated quality infrastructure, scalable capacity, digital manufacturing capabilities, and proven tech transfer models will command strategic value. The market’s long-term direction is clear: faster, more distributed, more compliant, more resilient, and increasingly data-driven vaccine manufacturing.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Vaccine Contract Manufacturing Market, by Vaccine Type

7.1. Introduction
7.2. DNA
7.3. Inactivated
7.4. Live Attenuated
7.5. MRNA
7.6. Toxoid
7.7. Viral Vector

8. Vaccine Contract Manufacturing Market, by Technology Platform

8.1. Introduction
8.2. Cell Based
8.2.1. Adherent Cell Culture
8.2.2. Suspension Cell Culture
8.3. Cell Free
8.4. Egg Based
8.5. Synthetic Peptide

9. Vaccine Contract Manufacturing Market, by Service Offering

9.1. Introduction
9.2. Analytical Services
9.3. Drug Substance Manufacturing
9.4. Fill Finish
9.5. Formulation Services
9.6. Logistics
9.7. Packaging

10. Vaccine Contract Manufacturing Market, by Application Type

10.1. Introduction
10.2. Preventive Vaccines
10.3. Therapeutic Vaccines

11. Vaccine Contract Manufacturing Market, by Application Stage

11.1. Introduction
11.2. Clinical Stage
11.2.1. Phase I
11.2.2. Phase Ii
11.2.3. Phase Iii
11.3. Commercial Stage

12. Vaccine Contract Manufacturing Market, by End User

12.1. Introduction
12.2. Biotech Companies
12.3. Government Agencies
12.4. Pharmaceutical Companies

13. Vaccine Contract Manufacturing Market, by Region

13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa

14. Vaccine Contract Manufacturing Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Vaccine Contract Manufacturing Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. Competitive Landscape

16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025

17. Company Profiles

17.1. AbbVie Inc
17.2. Ajinomoto Co., Inc.
17.3. Alcami Corporation, Inc.
17.4. Aton (Shanghai) Biotech Co., Ltd.
17.5. Avid Bioservices, Inc.
17.6. Batavia Biosciences B.V.
17.7. BioReliance Corporation
17.8. Catalent, Inc.
17.9. Charles River Laboratories International, Inc.
17.10. Cobra Biologics Limited
17.11. CSL Limited
17.12. Curia Global, Inc.
17.13. Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
17.14. Emergent BioSolutions Inc.
17.15. Eurogentec S.A.
17.16. FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
17.17. Gedeon Richter PLC
17.18. GlaxoSmithKline PLC
17.19. Grand River Aseptic Manufacturing, Inc.
17.20. HIPRA Human Health, S.L.U.
17.21. ICON PLC
17.22. IDT Biologika GmbH
17.23. KBI Biopharma, Inc. by JSR Corporation
17.24. Klocke Pharma-Service GmbH
17.25. Laboratorios Farmacéuticos Rovi, S.A.
17.26. Lonza Group Ltd.
17.27. Merck KGaA
17.28. Moderna, Inc.
17.29. Ology Bioservices, Inc.
17.30. Oxford Biomedica plc
17.31. Pfizer Inc.
17.32. Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
17.33. Piramal Pharma Limited
17.34. Recipharm AB
17.35. Serum Institute of India
17.36. Toyobo Co., Ltd.
17.37. Vetter Pharma-Fertigung GmbH & Co. KG
17.38. WuXi AppTec Co., Ltd.

List of Figures

FIGURE 1. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2032 (%)
FIGURE 9. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025 VS 2032 (%)
FIGURE 11. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025 VS 2032 (%)
FIGURE 13. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025 VS 2032 (%)
FIGURE 15. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

List of Tables

TABLE 1. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL DNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL DNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL DNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL INACTIVATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL INACTIVATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL INACTIVATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL LIVE ATTENUATED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL LIVE ATTENUATED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL LIVE ATTENUATED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL MRNA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL MRNA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL MRNA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL TOXOID MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL TOXOID MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL TOXOID MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL VIRAL VECTOR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL VIRAL VECTOR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL VIRAL VECTOR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL CELL BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL CELL BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL CELL BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL ADHERENT CELL CULTURE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL ADHERENT CELL CULTURE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL ADHERENT CELL CULTURE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL SUSPENSION CELL CULTURE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SUSPENSION CELL CULTURE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SUSPENSION CELL CULTURE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL CELL FREE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL CELL FREE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CELL FREE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL EGG BASED MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL EGG BASED MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL EGG BASED MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL SYNTHETIC PEPTIDE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL SYNTHETIC PEPTIDE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL SYNTHETIC PEPTIDE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL ANALYTICAL SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL ANALYTICAL SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL ANALYTICAL SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL DRUG SUBSTANCE MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL DRUG SUBSTANCE MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL DRUG SUBSTANCE MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL FILL FINISH MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL FILL FINISH MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL FILL FINISH MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL FORMULATION SERVICES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL FORMULATION SERVICES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL FORMULATION SERVICES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL LOGISTICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL LOGISTICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL LOGISTICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL PACKAGING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL PACKAGING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL PACKAGING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL PREVENTIVE VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL THERAPEUTIC VACCINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL CLINICAL STAGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL CLINICAL STAGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL CLINICAL STAGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL PHASE I MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL PHASE II MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL PHASE III MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL COMMERCIAL STAGE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL COMMERCIAL STAGE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL COMMERCIAL STAGE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL BIOTECH COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL BIOTECH COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL BIOTECH COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL GOVERNMENT AGENCIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL GOVERNMENT AGENCIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL GOVERNMENT AGENCIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL PHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 102. ASIA-PACIFIC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 112. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 121. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 122. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 123. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 124. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 125. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 126. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 127. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 128. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 129. EUROPE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 130. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 131. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 132. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 133. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 134. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 139. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 140. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 141. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 142. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 143. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 144. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 145. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 146. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 147. AFRICA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 148. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 149. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 150. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 151. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 152. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 153. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 154. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 155. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 156. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 157. ASEAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 158. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 160. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 161. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 162. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 163. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 164. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 165. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 166. GCC VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 167. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 168. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 169. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 170. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 171. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 172. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 173. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 174. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 175. EUROPEAN UNION VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 176. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 177. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 178. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 179. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 180. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 181. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 182. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 183. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 184. BRICS VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 185. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 186. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 187. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 188. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 189. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 190. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 191. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 192. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 193. G7 VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 194. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 195. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 196. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 197. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 198. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 199. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 200. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 201. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 202. NATO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 203. GLOBAL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 204. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 205. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 206. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 207. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 208. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 209. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 210. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 211. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 212. UNITED STATES VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 213. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 214. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 215. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 216. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 217. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 218. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 219. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 220. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 221. CANADA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 223. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 224. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 225. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 226. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 227. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 228. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 229. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 230. MEXICO VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 231. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 232. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 233. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 234. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 235. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 236. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 237. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 238. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 239. BRAZIL VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 240. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 241. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 242. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 243. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 244. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 245. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 246. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 247. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 248. UNITED KINGDOM VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 249. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 250. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 251. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 252. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 253. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 254. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 255. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 256. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 257. GERMANY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 258. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 259. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 260. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 261. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 262. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 263. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 264. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 265. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 266. FRANCE VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 267. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 268. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 269. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 270. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 271. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 272. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 273. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 274. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 275. RUSSIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 276. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 277. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 278. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 279. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 280. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 281. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 282. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 283. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 284. ITALY VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 285. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 286. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 287. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 288. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 289. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 290. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 291. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 292. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 293. SPAIN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 294. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 295. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 296. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 297. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 298. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 299. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 300. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 301. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 302. CHINA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 303. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 304. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 305. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 306. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 307. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 308. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 309. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 310. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 311. INDIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 312. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 313. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 314. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 315. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 316. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 317. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 318. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 319. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 320. JAPAN VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 321. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 322. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 323. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 324. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 325. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY SERVICE OFFERING, 2017-2032 (USD MILLION)
TABLE 326. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION TYPE, 2017-2032 (USD MILLION)
TABLE 327. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY APPLICATION STAGE, 2017-2032 (USD MILLION)
TABLE 328. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL STAGE, 2017-2032 (USD MILLION)
TABLE 329. AUSTRALIA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 330. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 331. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY VACCINE TYPE, 2017-2032 (USD MILLION)
TABLE 332. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2017-2032 (USD MILLION)
TABLE 333. SOUTH KOREA VACCINE CONTRACT MANUFACTURING MARKET SIZE, BY CELL BASED, 2017-2032 (USD MILLION)
TABLE 334. SOUTH KOREA VACCINE CONTRACT M

Companies Mentioned

AbbVie Inc
Ajinomoto Co., Inc.
Alcami Corporation, Inc.
Aton (Shanghai) Biotech Co., Ltd.
Avid Bioservices, Inc.
Batavia Biosciences B.V.
BioReliance Corporation
Catalent, Inc.
Charles River Laboratories International, Inc.
Cobra Biologics Limited
CSL Limited
Curia Global, Inc.
Cytovance Biologics by Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Emergent BioSolutions Inc.
Eurogentec S.A.
FUJIFILM Diosynth Biotechnologies U.S.A., Inc. by FUJIFILM Corporation
Gedeon Richter PLC
GlaxoSmithKline PLC
Grand River Aseptic Manufacturing, Inc.
HIPRA Human Health, S.L.U.
ICON PLC
IDT Biologika GmbH
KBI Biopharma, Inc. by JSR Corporation
Klocke Pharma-Service GmbH
Laboratorios Farmacéuticos Rovi, S.A.
Lonza Group Ltd.
Merck KGaA
Moderna, Inc.
Ology Bioservices, Inc.
Oxford Biomedica plc
Pfizer Inc.
Pharmaceutical Product Development by Thermo Fisher Scientific Inc.
Piramal Pharma Limited
Recipharm AB
Serum Institute of India
Toyobo Co., Ltd.
Vetter Pharma-Fertigung GmbH & Co. KG
WuXi AppTec Co., Ltd.

Table Information

Report Attribute	Details
No. of Pages	192
Published	August 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 6.56 Billion
Forecasted Market Value ( USD ) by 2032	$ 11.43 Billion
Compound Annual Growth Rate	9.5%
Regions Covered	Global
No. of Companies Mentioned	39

License	Format	Properties	Price
1 - 5 USER LICENSE PDF, Excel and Online Access		This is a 1-5 user license, allowing up to five users have access to the product.	€3184EUR$3,545USD£2,720GBP €3538EUR$3,939USD£3,022GBP
ENTERPRISE LICENSE PDF, Excel and Online Access		This is an enterprise license, allowing all employees within your organization access to the product.	€4817EUR$5,363USD£4,115GBP €5352EUR$5,959USD£4,572GBP

Transformative Shifts in the Vaccine Manufacturing Landscape

Cumulative Impact of Artificial Intelligence

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

Key Country Insights Across Major Vaccine Contract Manufacturing Markets

Actionable Recommendations for Industry Leaders

Research Methodology

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

mRNA Vaccine Drugs Development Services Market - Global Forecast 2026-2032

DNA Vaccine Market - Global Forecast 2026-2032

Vaccine Contract Manufacturing - Global Strategic Business Report

Bacillus Calmette-Guérin (BCG) Vaccines - Global Strategic Business Report

Vaccines Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration and Key Geographical Region